According to BBC investigation findings, diclegis access across English NHS trusts reveals stark regional disparities: 45% of trusts provide formulary coverage, 38% maintain restricted access policies, and 17% offer no coverage whatsoever. This fragmented landscape directly impacts pregnant women experiencing moderate-to-severe nausea and vomiting, a condition affecting the majority of pregnancies.
The statistical variation underscores a fundamental equity challenge within the NHS. Pregnant patients in well-funded trusts with formulary access receive evidence-based treatment for a condition with documented safety across regulatory agencies, while those in non-compliant trusts face either private costs or restricted alternatives. Given that nausea and vomiting in pregnancy can significantly impair quality of life and clinical outcomes, this postcode-dependent access creates inconsistent standards of maternal care.
These findings prompt critical examination of how formulary decisions are made across trusts and whether consistent, evidence-based guidance should standardise access to approved pregnancy medications nationwide.
Read the full article on GMJ Newsroom.
Was this article helpful?
